Spaces:
Running
Running
File size: 108,496 Bytes
9754890 |
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656 657 658 659 660 661 662 663 664 665 666 667 668 669 670 671 672 673 674 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 761 762 763 764 765 766 767 768 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788 789 790 791 792 793 794 795 796 797 798 799 800 801 802 803 804 805 806 807 808 809 810 811 812 813 814 815 816 817 818 819 820 821 822 823 824 825 826 827 828 829 830 831 832 833 834 835 836 837 838 839 840 841 842 843 844 845 846 847 848 849 850 851 852 853 854 855 856 857 858 859 860 861 862 863 864 865 866 867 868 869 870 871 872 873 874 875 876 877 878 879 880 881 882 883 884 885 886 887 888 889 890 891 892 893 894 895 896 897 898 899 900 901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 916 917 918 919 920 921 922 923 924 925 926 927 928 929 930 931 932 933 934 935 936 937 938 939 940 941 942 943 944 945 946 947 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 970 971 972 973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000 1001 1002 1003 1004 1005 1006 1007 1008 1009 1010 1011 1012 1013 1014 1015 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025 1026 1027 1028 1029 1030 1031 1032 1033 1034 1035 1036 1037 1038 1039 1040 1041 1042 1043 1044 1045 1046 1047 1048 1049 1050 1051 1052 1053 1054 1055 1056 1057 1058 1059 1060 1061 1062 1063 1064 1065 1066 1067 1068 1069 1070 1071 1072 1073 1074 1075 1076 1077 1078 1079 1080 1081 1082 1083 1084 1085 1086 1087 1088 1089 1090 1091 1092 1093 1094 1095 1096 1097 1098 1099 1100 1101 1102 1103 1104 1105 1106 1107 1108 1109 1110 1111 1112 1113 1114 1115 1116 1117 1118 1119 1120 1121 1122 1123 1124 1125 1126 1127 1128 1129 1130 1131 1132 1133 1134 1135 1136 1137 1138 1139 1140 1141 1142 1143 1144 1145 1146 1147 1148 1149 1150 1151 1152 1153 1154 1155 1156 1157 1158 1159 1160 1161 1162 1163 1164 1165 1166 1167 1168 1169 1170 1171 1172 1173 1174 1175 1176 1177 1178 1179 1180 1181 1182 1183 1184 1185 1186 1187 1188 1189 1190 1191 1192 1193 1194 1195 1196 1197 1198 1199 1200 1201 1202 1203 1204 1205 1206 1207 1208 1209 1210 1211 1212 1213 1214 1215 1216 1217 1218 1219 1220 1221 1222 1223 1224 1225 1226 1227 1228 1229 1230 1231 1232 1233 1234 1235 1236 1237 1238 1239 1240 1241 1242 1243 1244 1245 1246 1247 1248 1249 1250 1251 1252 1253 1254 1255 1256 1257 1258 1259 1260 1261 1262 1263 1264 1265 1266 1267 1268 1269 1270 1271 1272 1273 1274 1275 1276 1277 1278 1279 1280 1281 1282 1283 1284 1285 1286 1287 1288 1289 1290 1291 1292 1293 1294 1295 1296 1297 1298 1299 1300 1301 1302 1303 1304 1305 1306 1307 1308 1309 1310 1311 1312 1313 1314 1315 1316 1317 1318 1319 1320 1321 1322 1323 1324 1325 1326 1327 1328 1329 1330 1331 1332 1333 1334 1335 1336 1337 1338 1339 1340 1341 1342 1343 1344 1345 1346 1347 1348 1349 1350 1351 1352 1353 1354 1355 1356 1357 1358 1359 1360 1361 1362 1363 1364 1365 1366 1367 1368 1369 1370 1371 1372 1373 1374 1375 1376 1377 1378 1379 1380 1381 1382 1383 1384 1385 1386 1387 1388 1389 1390 1391 1392 1393 1394 1395 1396 1397 1398 1399 1400 1401 1402 1403 1404 1405 1406 1407 1408 1409 1410 1411 1412 1413 1414 1415 1416 1417 1418 1419 1420 1421 1422 1423 1424 1425 1426 1427 1428 1429 1430 1431 1432 1433 1434 1435 1436 1437 1438 1439 1440 1441 1442 1443 1444 1445 1446 1447 1448 1449 1450 1451 1452 1453 1454 1455 1456 1457 1458 1459 1460 1461 1462 1463 1464 1465 1466 1467 1468 1469 1470 1471 1472 1473 1474 1475 1476 1477 1478 1479 1480 1481 1482 1483 1484 1485 1486 1487 1488 1489 1490 1491 1492 1493 1494 1495 1496 1497 1498 1499 1500 1501 1502 1503 1504 1505 1506 1507 1508 1509 1510 1511 1512 1513 1514 1515 1516 1517 1518 1519 1520 1521 1522 1523 1524 1525 1526 1527 1528 1529 1530 1531 1532 1533 1534 1535 1536 1537 1538 1539 1540 1541 1542 1543 1544 1545 1546 1547 1548 1549 1550 1551 1552 1553 1554 1555 1556 1557 1558 1559 1560 1561 1562 1563 1564 1565 1566 1567 1568 1569 1570 1571 1572 1573 1574 1575 1576 1577 1578 1579 1580 1581 1582 1583 1584 1585 1586 1587 1588 1589 1590 1591 1592 1593 1594 1595 1596 1597 1598 1599 1600 1601 1602 1603 1604 1605 1606 1607 1608 1609 1610 1611 1612 1613 1614 1615 1616 1617 1618 1619 1620 1621 1622 1623 1624 1625 1626 1627 1628 1629 1630 1631 1632 1633 1634 1635 1636 1637 1638 1639 1640 1641 1642 1643 1644 1645 1646 1647 1648 1649 1650 1651 1652 1653 1654 1655 1656 1657 1658 1659 1660 1661 1662 1663 1664 1665 1666 1667 1668 1669 1670 1671 1672 1673 1674 1675 1676 1677 1678 1679 1680 1681 1682 1683 1684 1685 1686 1687 1688 1689 1690 1691 1692 1693 1694 1695 1696 1697 1698 1699 1700 1701 1702 1703 1704 1705 1706 1707 1708 1709 1710 1711 1712 1713 1714 1715 1716 1717 1718 1719 1720 1721 1722 1723 1724 1725 1726 1727 1728 1729 1730 1731 1732 1733 1734 1735 1736 1737 1738 1739 1740 1741 1742 1743 1744 1745 1746 1747 1748 1749 1750 1751 1752 1753 1754 1755 1756 1757 1758 1759 1760 1761 1762 1763 1764 1765 1766 1767 1768 1769 1770 1771 1772 1773 1774 1775 1776 1777 1778 1779 1780 1781 1782 1783 1784 1785 1786 1787 1788 1789 1790 1791 1792 1793 1794 1795 1796 1797 1798 1799 1800 1801 1802 1803 1804 1805 1806 1807 1808 1809 1810 1811 1812 1813 1814 1815 1816 1817 1818 1819 1820 1821 1822 1823 1824 1825 1826 1827 1828 1829 1830 1831 1832 1833 1834 1835 1836 1837 1838 1839 1840 1841 1842 1843 1844 1845 1846 1847 1848 1849 1850 1851 1852 1853 1854 1855 1856 1857 1858 1859 1860 1861 1862 1863 1864 1865 1866 1867 1868 1869 1870 1871 1872 1873 1874 1875 1876 1877 1878 1879 1880 1881 1882 1883 1884 1885 1886 1887 1888 1889 1890 1891 1892 1893 1894 1895 1896 1897 1898 1899 1900 1901 1902 1903 1904 1905 1906 1907 1908 1909 1910 1911 1912 1913 1914 1915 1916 1917 1918 1919 1920 1921 1922 1923 1924 1925 1926 1927 1928 1929 1930 1931 1932 1933 1934 1935 1936 1937 1938 1939 1940 1941 1942 1943 1944 1945 1946 1947 1948 1949 1950 1951 1952 1953 1954 1955 1956 1957 1958 1959 1960 1961 1962 1963 1964 1965 1966 1967 1968 1969 1970 1971 1972 1973 1974 1975 1976 1977 1978 1979 1980 1981 1982 1983 1984 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 2036 2037 2038 2039 2040 2041 2042 2043 2044 2045 2046 2047 2048 2049 2050 2051 |
{
"cells": [
{
"cell_type": "code",
"execution_count": 1,
"metadata": {},
"outputs": [
{
"name": "stderr",
"output_type": "stream",
"text": [
"/Users/satoc/miniforge3/envs/gradio/lib/python3.12/site-packages/sentence_transformers/cross_encoder/CrossEncoder.py:13: TqdmExperimentalWarning: Using `tqdm.autonotebook.tqdm` in notebook mode. Use `tqdm.tqdm` instead to force console mode (e.g. in jupyter console)\n",
" from tqdm.autonotebook import tqdm, trange\n"
]
}
],
"source": [
"from sentence_transformers import SentenceTransformer, util\n",
"import pandas as pd\n",
"import re"
]
},
{
"cell_type": "code",
"execution_count": 14,
"metadata": {},
"outputs": [],
"source": [
"# Target列を分割する関数\n",
"def split_target(target):\n",
" # 指定された区切り文字で分割\n",
" split_words = re.split(r'[,\\n、・及びおよび又はまたは]+', target)\n",
" # 空白文字を除外してリストとして返す\n",
" return [word.strip() for word in split_words if word.strip()]\n",
"\n",
"\n",
"# Target列を分割する関数（改良後）\n",
"def split_target_English(target):\n",
" # 区切り文字を (,) or (\\n) or (、) or (・) または文字列\"or\" として扱う\n",
" # 正規表現では、パイプ(|)でor条件を定義し、\"(?: ... )\"はグルーピングのみ行う非捕捉グループ\n",
" # [,\\n、・] はいずれかの1文字とマッチ\n",
" # or は文字列全体とマッチ\n",
" # 複数連続した区切り文字をまとめて1回の分割として扱うために+(1回以上)とする\n",
" split_words = re.split(r'(?:[,\\n、・]|or)+', target)\n",
" \n",
" # 空白文字を除外してリストとして返す\n",
" return [word.strip() for word in split_words if word.strip()]"
]
},
{
"cell_type": "code",
"execution_count": 15,
"metadata": {},
"outputs": [],
"source": [
"basedf = pd.read_csv('../ClinicalTrialCSV/JRCT20241215Cancer.csv', index_col=0)\n",
"basedf = basedf.dropna(subset=['試験等のフェーズ'])\n",
"# Target列を分割してTargetWord列を追加\n",
"basedf['TargetWord'] = basedf['TargetEnglish'].apply(split_target_English)"
]
},
{
"cell_type": "code",
"execution_count": 16,
"metadata": {},
"outputs": [
{
"data": {
"text/html": [
"<div>\n",
"<style scoped>\n",
" .dataframe tbody tr th:only-of-type {\n",
" vertical-align: middle;\n",
" }\n",
"\n",
" .dataframe tbody tr th {\n",
" vertical-align: top;\n",
" }\n",
"\n",
" .dataframe thead th {\n",
" text-align: right;\n",
" }\n",
"</style>\n",
"<table border=\"1\" class=\"dataframe\">\n",
" <thead>\n",
" <tr style=\"text-align: right;\">\n",
" <th></th>\n",
" <th>JRCT ID</th>\n",
" <th>NCT No</th>\n",
" <th>JapicCTI No</th>\n",
" <th>Title</th>\n",
" <th>TargetJ</th>\n",
" <th>Target</th>\n",
" <th>TargetEnglish</th>\n",
" <th>研究・治験の目的</th>\n",
" <th>試験等のフェーズ</th>\n",
" <th>試験の種類</th>\n",
" <th>...</th>\n",
" <th>purpose</th>\n",
" <th>Inclusion Criteria</th>\n",
" <th>Exclusion Criteria</th>\n",
" <th>Age Minimum</th>\n",
" <th>Age Maximum</th>\n",
" <th>Gender</th>\n",
" <th>Discontinuation Criteria</th>\n",
" <th>Keyword</th>\n",
" <th>Intervention(s)</th>\n",
" <th>TargetWord</th>\n",
" </tr>\n",
" </thead>\n",
" <tbody>\n",
" <tr>\n",
" <th>0</th>\n",
" <td>jRCT2031240552</td>\n",
" <td>NCT06599502</td>\n",
" <td>NaN</td>\n",
" <td>KRAS G12D 変異陽性がん患者を対象としてAZD0022 の単剤療法及び抗がん剤との併...</td>\n",
" <td>以下の進行固形がん患者\\n・非小細胞肺癌\\n・膵管腺癌\\n・結腸・直腸癌</td>\n",
" <td>以下の進行固形がん患者 ・非小細胞肺癌 ・膵管腺癌 ・結腸・直腸癌</td>\n",
" <td>Non-Small Cell Lung Cancer (NSCLC) Pancreatic ...</td>\n",
" <td>Treatment</td>\n",
" <td>1-2</td>\n",
" <td>NaN</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>1. Participant must be 18 years or more, or th...</td>\n",
" <td>1. Any significant laboratory finding or any s...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>AZD0022</td>\n",
" <td>[Non-Small Cell Lung Cancer (NSCLC) Pancreatic...</td>\n",
" </tr>\n",
" <tr>\n",
" <th>3</th>\n",
" <td>jRCT2031240547</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>FGFR2b陽性切除不能進行・再発の胃または食道胃接合部腺癌を対象としたBemarituzu...</td>\n",
" <td>切除不能進行・再発の胃または食道胃接合部腺癌</td>\n",
" <td>切除不能進行・再発の胃または食道胃接合部腺癌</td>\n",
" <td>Advanced Gastric or Gastroesophageal Junction ...</td>\n",
" <td>フッ化ピリミジン系薬剤に不応または不耐となったFGFR2b陽性の切除不能進行・再発の胃腺癌又...</td>\n",
" <td>2</td>\n",
" <td>NaN</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>1) Histologically documented gastric or GEJ ad...</td>\n",
" <td>1) Prior treatment with taxanes 2) Prior treat...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>- Bemarituzumab (15mg/kg, intravenous, Day1, 1...</td>\n",
" <td>[Advanced Gastric, Gastroesophageal Junction C...</td>\n",
" </tr>\n",
" <tr>\n",
" <th>5</th>\n",
" <td>jRCT2031240542</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>自家造血幹細胞移植非適応の初発多発性骨髄腫患者を対象としてベランタマブ マホドチンとレナリド...</td>\n",
" <td>多発性骨髄腫</td>\n",
" <td>多発性骨髄腫</td>\n",
" <td>Multiple Myeloma</td>\n",
" <td>自家造血幹細胞移植非適応の初発多発性骨髄腫を対象にGSK2857916、レナリドミド 及び ...</td>\n",
" <td>3</td>\n",
" <td>NaN</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>1. Is at least 18 or the legal age of consent ...</td>\n",
" <td>Participants are excluded from the study if an...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Arm A: Belantamab Mafodotin is intraveniously ...</td>\n",
" <td>[Multiple Myeloma]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>7</th>\n",
" <td>jRCT2031240536</td>\n",
" <td>NCT06003231</td>\n",
" <td>NaN</td>\n",
" <td>既治療の局所進行切除不能又は転移性HER2発現固形癌を有する成人患者を対象としたDisita...</td>\n",
" <td>頭頸部扁平上皮癌、非小細胞肺癌、卵巣癌、子宮内膜癌</td>\n",
" <td>頭頸部扁平上皮癌、非小細胞肺癌、卵巣癌、子宮内膜癌</td>\n",
" <td>Head and neck squamous cell carcinoma/Non-smal...</td>\n",
" <td>既治療の局所進行切除不能又は転移性(LA/m)ヒト上皮増殖因子受容体2型(HER2)発現固形...</td>\n",
" <td>2</td>\n",
" <td>NaN</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>Cohort 1: Head and neck squamous cell carcinom...</td>\n",
" <td>- Prior treatment with a monomethyl auristatin...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Experimental Arm - Disitamab vedotin 1.5 mg/kg...</td>\n",
" <td>[Head and neck squamous cell carcinoma/Non-sma...</td>\n",
" </tr>\n",
" <tr>\n",
" <th>9</th>\n",
" <td>jRCT2031240530</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>HER2遺伝子増幅あるいはHER2遺伝子変異を有するII-III期非小細胞肺癌に対するTra...</td>\n",
" <td>HER2遺伝子増幅あるいはHER2遺伝子変異を有するII/IIIA/IIIB(T3-4N2)...</td>\n",
" <td>HER2遺伝子増幅あるいはHER2遺伝子変異を有するII/IIIA/IIIB(T3-4N2)...</td>\n",
" <td>Stage II-III HER2-Amplified or HER2-Mutant Non...</td>\n",
" <td>HER2遺伝子増幅あるいはHER2遺伝子変異を有するII/IIIA/IIIB(T3-4N2)...</td>\n",
" <td>2</td>\n",
" <td>NaN</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>1. Signed informed consent form 2. Age >= 18 y...</td>\n",
" <td>1. NSCLC that is clinically T4 by virtue of me...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>The study drug will be administered as an IV i...</td>\n",
" <td>[Stage II-III HER2-Amplified, HER2-Mutant Non-...</td>\n",
" </tr>\n",
" <tr>\n",
" <th>...</th>\n",
" <td>...</td>\n",
" <td>...</td>\n",
" <td>...</td>\n",
" <td>...</td>\n",
" <td>...</td>\n",
" <td>...</td>\n",
" <td>...</td>\n",
" <td>...</td>\n",
" <td>...</td>\n",
" <td>...</td>\n",
" <td>...</td>\n",
" <td>...</td>\n",
" <td>...</td>\n",
" <td>...</td>\n",
" <td>...</td>\n",
" <td>...</td>\n",
" <td>...</td>\n",
" <td>...</td>\n",
" <td>...</td>\n",
" <td>...</td>\n",
" <td>...</td>\n",
" </tr>\n",
" <tr>\n",
" <th>729</th>\n",
" <td>jRCT2031200057</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>治療抵抗性乳がんを対象としたTDM-812の腫瘍内投与法の安全性評価を目的とした第I相試験</td>\n",
" <td>乳がん</td>\n",
" <td>乳がん</td>\n",
" <td>Breast cancer</td>\n",
" <td>TDM-812の腫瘍内投与の安全性および忍容性を評価し、今後の臨床評価に用いる腫瘍内投与にお...</td>\n",
" <td>1</td>\n",
" <td>NaN</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td><Disease Characteristics> 1)Patients with inop...</td>\n",
" <td>1)Patients correspond to either of the followi...</td>\n",
" <td>20age old over</td>\n",
" <td>No limit</td>\n",
" <td>Female</td>\n",
" <td>NaN</td>\n",
" <td>Breast cancer</td>\n",
" <td>For the target tumor, the dose settled at each...</td>\n",
" <td>[Breast cancer]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>739</th>\n",
" <td>jRCT2073200004</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>切除不能膵癌を対象とした腫瘍溶解性ウイルスの腫瘍内局所投与の臨床第Ⅰ/Ⅱ相試験</td>\n",
" <td>膵癌</td>\n",
" <td>膵癌</td>\n",
" <td>Pancreatic cancer</td>\n",
" <td>切除不能膵癌患者に対するSurv.m-CRA-1の腫瘍内投与の安全性及び有効性を検討する。</td>\n",
" <td>1-2</td>\n",
" <td>NaN</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>The patients with pancreatic tumors must meet ...</td>\n",
" <td>1) Patients with the following complications: ...</td>\n",
" <td>20age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>Pancreatic ductal carcinoma, unresectable</td>\n",
" <td>Intratumoral administration of oncolytic virus</td>\n",
" <td>[Pancreatic cancer]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>760</th>\n",
" <td>jRCT2033190086</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>悪性黒色腫患者を対象としたインターロイキン12発現型遺伝子組換え単純ヘルペスウイルス１型の第...</td>\n",
" <td>悪性黒色腫</td>\n",
" <td>悪性黒色腫</td>\n",
" <td>malignant melanoma</td>\n",
" <td>第I相パート:進行期の悪性黒色腫患者を対象として、ヒトIL-12発現型遺伝子組換え単純ヘルペ...</td>\n",
" <td>1-2</td>\n",
" <td>NaN</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>(Phase 1) 1) Histologically confirmed malignan...</td>\n",
" <td>(Phase 1 and 2) 1) Patients who have brain and...</td>\n",
" <td>20age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>malignamt melanoma, advanced stage</td>\n",
" <td>Test drug (T-hIL12) will be administered into ...</td>\n",
" <td>[malignant melanoma]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>762</th>\n",
" <td>jRCT2031190072</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>切除不能な進行肝細胞癌患者を対象としたCYT001の第I相臨床試験</td>\n",
" <td>肝細胞癌</td>\n",
" <td>肝細胞癌</td>\n",
" <td>Hepatocellular carcinoma</td>\n",
" <td>切除不能な進行肝細胞癌患者を対象としたCYT001の第I相臨床試験</td>\n",
" <td>1</td>\n",
" <td>NaN</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>1) Histologically or cytologically confirmed h...</td>\n",
" <td>1) CNS metastases that are symptomatic or requ...</td>\n",
" <td>20age 0month 0week old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>Cancer peptide vaccine</td>\n",
" <td>Reconstitute two kinds of cancer peptide vacci...</td>\n",
" <td>[Hepatocellular carcinoma]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>772</th>\n",
" <td>jRCT2051190009</td>\n",
" <td>NCT03818893</td>\n",
" <td>JapicCTI-194618</td>\n",
" <td>進行性悪性黒色腫患者を対象としたGEN0101の皮内投与と、ペムブロリズマブ（抗PD-1抗体...</td>\n",
" <td>進行性悪性黒色腫</td>\n",
" <td>進行性悪性黒色腫</td>\n",
" <td>advanced melanoma</td>\n",
" <td>抗PD-1抗体治療でSDが確定した、またはPDとなった患者を対象とし、非盲検下でGEN010...</td>\n",
" <td>1-2</td>\n",
" <td>NaN</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>Inclusion criteria Patients meeting all of the...</td>\n",
" <td>Exclusion criteria Patients meeting any of the...</td>\n",
" <td>20age old over</td>\n",
" <td>86age old not</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>advanced melanoma</td>\n",
" <td>combination therapy of intracutaneous GEN0101 ...</td>\n",
" <td>[advanced melanoma]</td>\n",
" </tr>\n",
" </tbody>\n",
"</table>\n",
"<p>427 rows × 40 columns</p>\n",
"</div>"
],
"text/plain": [
" JRCT ID NCT No JapicCTI No \\\n",
"0 jRCT2031240552 NCT06599502 NaN \n",
"3 jRCT2031240547 NaN NaN \n",
"5 jRCT2031240542 NaN NaN \n",
"7 jRCT2031240536 NCT06003231 NaN \n",
"9 jRCT2031240530 NaN NaN \n",
".. ... ... ... \n",
"729 jRCT2031200057 NaN NaN \n",
"739 jRCT2073200004 NaN NaN \n",
"760 jRCT2033190086 NaN NaN \n",
"762 jRCT2031190072 NaN NaN \n",
"772 jRCT2051190009 NCT03818893 JapicCTI-194618 \n",
"\n",
" Title \\\n",
"0 KRAS G12D 変異陽性がん患者を対象としてAZD0022 の単剤療法及び抗がん剤との併... \n",
"3 FGFR2b陽性切除不能進行・再発の胃または食道胃接合部腺癌を対象としたBemarituzu... \n",
"5 自家造血幹細胞移植非適応の初発多発性骨髄腫患者を対象としてベランタマブ マホドチンとレナリド... \n",
"7 既治療の局所進行切除不能又は転移性HER2発現固形癌を有する成人患者を対象としたDisita... \n",
"9 HER2遺伝子増幅あるいはHER2遺伝子変異を有するII-III期非小細胞肺癌に対するTra... \n",
".. ... \n",
"729 治療抵抗性乳がんを対象としたTDM-812の腫瘍内投与法の安全性評価を目的とした第I相試験 \n",
"739 切除不能膵癌を対象とした腫瘍溶解性ウイルスの腫瘍内局所投与の臨床第Ⅰ/Ⅱ相試験 \n",
"760 悪性黒色腫患者を対象としたインターロイキン12発現型遺伝子組換え単純ヘルペスウイルス１型の第... \n",
"762 切除不能な進行肝細胞癌患者を対象としたCYT001の第I相臨床試験 \n",
"772 進行性悪性黒色腫患者を対象としたGEN0101の皮内投与と、ペムブロリズマブ（抗PD-1抗体... \n",
"\n",
" TargetJ \\\n",
"0 以下の進行固形がん患者\\n・非小細胞肺癌\\n・膵管腺癌\\n・結腸・直腸癌 \n",
"3 切除不能進行・再発の胃または食道胃接合部腺癌 \n",
"5 多発性骨髄腫 \n",
"7 頭頸部扁平上皮癌、非小細胞肺癌、卵巣癌、子宮内膜癌 \n",
"9 HER2遺伝子増幅あるいはHER2遺伝子変異を有するII/IIIA/IIIB(T3-4N2)... \n",
".. ... \n",
"729 乳がん \n",
"739 膵癌 \n",
"760 悪性黒色腫 \n",
"762 肝細胞癌 \n",
"772 進行性悪性黒色腫 \n",
"\n",
" Target \\\n",
"0 以下の進行固形がん患者 ・非小細胞肺癌 ・膵管腺癌 ・結腸・直腸癌 \n",
"3 切除不能進行・再発の胃または食道胃接合部腺癌 \n",
"5 多発性骨髄腫 \n",
"7 頭頸部扁平上皮癌、非小細胞肺癌、卵巣癌、子宮内膜癌 \n",
"9 HER2遺伝子増幅あるいはHER2遺伝子変異を有するII/IIIA/IIIB(T3-4N2)... \n",
".. ... \n",
"729 乳がん \n",
"739 膵癌 \n",
"760 悪性黒色腫 \n",
"762 肝細胞癌 \n",
"772 進行性悪性黒色腫 \n",
"\n",
" TargetEnglish \\\n",
"0 Non-Small Cell Lung Cancer (NSCLC) Pancreatic ... \n",
"3 Advanced Gastric or Gastroesophageal Junction ... \n",
"5 Multiple Myeloma \n",
"7 Head and neck squamous cell carcinoma/Non-smal... \n",
"9 Stage II-III HER2-Amplified or HER2-Mutant Non... \n",
".. ... \n",
"729 Breast cancer \n",
"739 Pancreatic cancer \n",
"760 malignant melanoma \n",
"762 Hepatocellular carcinoma \n",
"772 advanced melanoma \n",
"\n",
" 研究・治験の目的 試験等のフェーズ 試験の種類 ... \\\n",
"0 Treatment 1-2 NaN ... \n",
"3 フッ化ピリミジン系薬剤に不応または不耐となったFGFR2b陽性の切除不能進行・再発の胃腺癌又... 2 NaN ... \n",
"5 自家造血幹細胞移植非適応の初発多発性骨髄腫を対象にGSK2857916、レナリドミド 及び ... 3 NaN ... \n",
"7 既治療の局所進行切除不能又は転移性(LA/m)ヒト上皮増殖因子受容体2型(HER2)発現固形... 2 NaN ... \n",
"9 HER2遺伝子増幅あるいはHER2遺伝子変異を有するII/IIIA/IIIB(T3-4N2)... 2 NaN ... \n",
".. ... ... ... ... \n",
"729 TDM-812の腫瘍内投与の安全性および忍容性を評価し、今後の臨床評価に用いる腫瘍内投与にお... 1 NaN ... \n",
"739 切除不能膵癌患者に対するSurv.m-CRA-1の腫瘍内投与の安全性及び有効性を検討する。 1-2 NaN ... \n",
"760 第I相パート:進行期の悪性黒色腫患者を対象として、ヒトIL-12発現型遺伝子組換え単純ヘルペ... 1-2 NaN ... \n",
"762 切除不能な進行肝細胞癌患者を対象としたCYT001の第I相臨床試験 1 NaN ... \n",
"772 抗PD-1抗体治療でSDが確定した、またはPDとなった患者を対象とし、非盲検下でGEN010... 1-2 NaN ... \n",
"\n",
" purpose Inclusion Criteria \\\n",
"0 treatment purpose 1. Participant must be 18 years or more, or th... \n",
"3 treatment purpose 1) Histologically documented gastric or GEJ ad... \n",
"5 treatment purpose 1. Is at least 18 or the legal age of consent ... \n",
"7 treatment purpose Cohort 1: Head and neck squamous cell carcinom... \n",
"9 treatment purpose 1. Signed informed consent form 2. Age >= 18 y... \n",
".. ... ... \n",
"729 treatment purpose <Disease Characteristics> 1)Patients with inop... \n",
"739 treatment purpose The patients with pancreatic tumors must meet ... \n",
"760 treatment purpose (Phase 1) 1) Histologically confirmed malignan... \n",
"762 treatment purpose 1) Histologically or cytologically confirmed h... \n",
"772 treatment purpose Inclusion criteria Patients meeting all of the... \n",
"\n",
" Exclusion Criteria \\\n",
"0 1. Any significant laboratory finding or any s... \n",
"3 1) Prior treatment with taxanes 2) Prior treat... \n",
"5 Participants are excluded from the study if an... \n",
"7 - Prior treatment with a monomethyl auristatin... \n",
"9 1. NSCLC that is clinically T4 by virtue of me... \n",
".. ... \n",
"729 1)Patients correspond to either of the followi... \n",
"739 1) Patients with the following complications: ... \n",
"760 (Phase 1 and 2) 1) Patients who have brain and... \n",
"762 1) CNS metastases that are symptomatic or requ... \n",
"772 Exclusion criteria Patients meeting any of the... \n",
"\n",
" Age Minimum Age Maximum Gender \\\n",
"0 18age old over No limit Both \n",
"3 18age old over No limit Both \n",
"5 18age old over No limit Both \n",
"7 18age old over No limit Both \n",
"9 18age old over No limit Both \n",
".. ... ... ... \n",
"729 20age old over No limit Female \n",
"739 20age old over No limit Both \n",
"760 20age old over No limit Both \n",
"762 20age 0month 0week old over No limit Both \n",
"772 20age old over 86age old not Both \n",
"\n",
" Discontinuation Criteria Keyword \\\n",
"0 NaN NaN \n",
"3 NaN NaN \n",
"5 NaN NaN \n",
"7 NaN NaN \n",
"9 NaN NaN \n",
".. ... ... \n",
"729 NaN Breast cancer \n",
"739 NaN Pancreatic ductal carcinoma, unresectable \n",
"760 NaN malignamt melanoma, advanced stage \n",
"762 NaN Cancer peptide vaccine \n",
"772 NaN advanced melanoma \n",
"\n",
" Intervention(s) \\\n",
"0 AZD0022 \n",
"3 - Bemarituzumab (15mg/kg, intravenous, Day1, 1... \n",
"5 Arm A: Belantamab Mafodotin is intraveniously ... \n",
"7 Experimental Arm - Disitamab vedotin 1.5 mg/kg... \n",
"9 The study drug will be administered as an IV i... \n",
".. ... \n",
"729 For the target tumor, the dose settled at each... \n",
"739 Intratumoral administration of oncolytic virus \n",
"760 Test drug (T-hIL12) will be administered into ... \n",
"762 Reconstitute two kinds of cancer peptide vacci... \n",
"772 combination therapy of intracutaneous GEN0101 ... \n",
"\n",
" TargetWord \n",
"0 [Non-Small Cell Lung Cancer (NSCLC) Pancreatic... \n",
"3 [Advanced Gastric, Gastroesophageal Junction C... \n",
"5 [Multiple Myeloma] \n",
"7 [Head and neck squamous cell carcinoma/Non-sma... \n",
"9 [Stage II-III HER2-Amplified, HER2-Mutant Non-... \n",
".. ... \n",
"729 [Breast cancer] \n",
"739 [Pancreatic cancer] \n",
"760 [malignant melanoma] \n",
"762 [Hepatocellular carcinoma] \n",
"772 [advanced melanoma] \n",
"\n",
"[427 rows x 40 columns]"
]
},
"execution_count": 16,
"metadata": {},
"output_type": "execute_result"
}
],
"source": [
"basedf.dropna(subset=['TargetEnglish'])"
]
},
{
"cell_type": "code",
"execution_count": 17,
"metadata": {},
"outputs": [
{
"data": {
"application/vnd.jupyter.widget-view+json": {
"model_id": "67f75d0e635b41a488f77601d930e4d1",
"version_major": 2,
"version_minor": 0
},
"text/plain": [
"modules.json: 0%| | 0.00/349 [00:00<?, ?B/s]"
]
},
"metadata": {},
"output_type": "display_data"
},
{
"data": {
"application/vnd.jupyter.widget-view+json": {
"model_id": "1551a047d06c4c0887b8d6331389f475",
"version_major": 2,
"version_minor": 0
},
"text/plain": [
"config_sentence_transformers.json: 0%| | 0.00/116 [00:00<?, ?B/s]"
]
},
"metadata": {},
"output_type": "display_data"
},
{
"data": {
"application/vnd.jupyter.widget-view+json": {
"model_id": "8bb034be14554f05806e284e3978de5b",
"version_major": 2,
"version_minor": 0
},
"text/plain": [
"README.md: 0%| | 0.00/10.6k [00:00<?, ?B/s]"
]
},
"metadata": {},
"output_type": "display_data"
},
{
"data": {
"application/vnd.jupyter.widget-view+json": {
"model_id": "af1bf85af4e3424890881646a70db423",
"version_major": 2,
"version_minor": 0
},
"text/plain": [
"sentence_bert_config.json: 0%| | 0.00/53.0 [00:00<?, ?B/s]"
]
},
"metadata": {},
"output_type": "display_data"
},
{
"data": {
"application/vnd.jupyter.widget-view+json": {
"model_id": "a6c9c8577d0d44caa247b6c2ae60832a",
"version_major": 2,
"version_minor": 0
},
"text/plain": [
"config.json: 0%| | 0.00/571 [00:00<?, ?B/s]"
]
},
"metadata": {},
"output_type": "display_data"
},
{
"data": {
"application/vnd.jupyter.widget-view+json": {
"model_id": "db75a9d07771411d81d66195a4e1563c",
"version_major": 2,
"version_minor": 0
},
"text/plain": [
"model.safetensors: 0%| | 0.00/438M [00:00<?, ?B/s]"
]
},
"metadata": {},
"output_type": "display_data"
},
{
"data": {
"application/vnd.jupyter.widget-view+json": {
"model_id": "9c9cd9ebe0a04a5f8d57120405a97248",
"version_major": 2,
"version_minor": 0
},
"text/plain": [
"tokenizer_config.json: 0%| | 0.00/363 [00:00<?, ?B/s]"
]
},
"metadata": {},
"output_type": "display_data"
},
{
"data": {
"application/vnd.jupyter.widget-view+json": {
"model_id": "79c9feca90f14b6f88d9a1c175a74f8f",
"version_major": 2,
"version_minor": 0
},
"text/plain": [
"vocab.txt: 0%| | 0.00/232k [00:00<?, ?B/s]"
]
},
"metadata": {},
"output_type": "display_data"
},
{
"data": {
"application/vnd.jupyter.widget-view+json": {
"model_id": "26f5d87067cc4f3083c33b72e56a27a7",
"version_major": 2,
"version_minor": 0
},
"text/plain": [
"tokenizer.json: 0%| | 0.00/466k [00:00<?, ?B/s]"
]
},
"metadata": {},
"output_type": "display_data"
},
{
"data": {
"application/vnd.jupyter.widget-view+json": {
"model_id": "9a465b62659d41c3aa324d2e03902b51",
"version_major": 2,
"version_minor": 0
},
"text/plain": [
"special_tokens_map.json: 0%| | 0.00/239 [00:00<?, ?B/s]"
]
},
"metadata": {},
"output_type": "display_data"
},
{
"name": "stderr",
"output_type": "stream",
"text": [
"/Users/satoc/miniforge3/envs/gradio/lib/python3.12/site-packages/transformers/tokenization_utils_base.py:1617: FutureWarning: `clean_up_tokenization_spaces` was not set. It will be set to `True` by default. This behavior will be deprecated in transformers v4.45, and will be then set to `False` by default. For more details check this issue: https://github.com/huggingface/transformers/issues/31884\n",
" warnings.warn(\n"
]
},
{
"data": {
"application/vnd.jupyter.widget-view+json": {
"model_id": "25ed39dfce054cbc9306c3bea9ab1963",
"version_major": 2,
"version_minor": 0
},
"text/plain": [
"1_Pooling/config.json: 0%| | 0.00/190 [00:00<?, ?B/s]"
]
},
"metadata": {},
"output_type": "display_data"
}
],
"source": [
"# モデルのロード\n",
"model = SentenceTransformer('all-mpnet-base-v2')"
]
},
{
"cell_type": "code",
"execution_count": 52,
"metadata": {},
"outputs": [],
"source": [
"# クエリ\n",
"query = \"Triple negative breast cancer\"\n",
"query = \"breast cancer\"\n",
"#query = \"glioma\"\n",
"threshold = 0.7\n",
"# クエリをベクトル化\n",
"query_vec = model.encode(query, convert_to_tensor=True)\n"
]
},
{
"cell_type": "code",
"execution_count": 53,
"metadata": {},
"outputs": [
{
"data": {
"text/html": [
"<div>\n",
"<style scoped>\n",
" .dataframe tbody tr th:only-of-type {\n",
" vertical-align: middle;\n",
" }\n",
"\n",
" .dataframe tbody tr th {\n",
" vertical-align: top;\n",
" }\n",
"\n",
" .dataframe thead th {\n",
" text-align: right;\n",
" }\n",
"</style>\n",
"<table border=\"1\" class=\"dataframe\">\n",
" <thead>\n",
" <tr style=\"text-align: right;\">\n",
" <th></th>\n",
" <th>JRCT ID</th>\n",
" <th>NCT No</th>\n",
" <th>JapicCTI No</th>\n",
" <th>Title</th>\n",
" <th>TargetJ</th>\n",
" <th>Target</th>\n",
" <th>TargetEnglish</th>\n",
" <th>研究・治験の目的</th>\n",
" <th>試験等のフェーズ</th>\n",
" <th>試験の種類</th>\n",
" <th>...</th>\n",
" <th>purpose</th>\n",
" <th>Inclusion Criteria</th>\n",
" <th>Exclusion Criteria</th>\n",
" <th>Age Minimum</th>\n",
" <th>Age Maximum</th>\n",
" <th>Gender</th>\n",
" <th>Discontinuation Criteria</th>\n",
" <th>Keyword</th>\n",
" <th>Intervention(s)</th>\n",
" <th>TargetWord</th>\n",
" </tr>\n",
" </thead>\n",
" <tbody>\n",
" <tr>\n",
" <th>32</th>\n",
" <td>jRCT2031240476</td>\n",
" <td>NCT06312176</td>\n",
" <td>NaN</td>\n",
" <td>ホルモン受容体陽性・ヒト上皮成長因子受容体2陰性（HR+/HER2-）の切除不能な局所進行又...</td>\n",
" <td>HR+/HER2-の切除不能局所進行又は転移性乳癌の患者</td>\n",
" <td>HR+/HER2-の切除不能局所進行又は転移性乳癌の患者</td>\n",
" <td>HR+/HER2 unresectable locally advanced or meta...</td>\n",
" <td>HR+/HER2-の切除不能な局所進行又は転移性乳癌患者を対象にMK-2870の単剤及びペム...</td>\n",
" <td>3</td>\n",
" <td>NaN</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>-Has unresectable locally advanced or metastat...</td>\n",
" <td>-Has breast cancer amenable to treatment with ...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Arm A:MK-2870 Participants receive 4 mg/kg of ...</td>\n",
" <td>[HR+/HER2 unresectable locally advanced, metas...</td>\n",
" </tr>\n",
" <tr>\n",
" <th>112</th>\n",
" <td>jRCT2031240238</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>ネクチン-4発現に関連する進行性悪性腫瘍を有する日本人患者を対象にBT8009の安全性、薬物...</td>\n",
" <td>進行固形癌</td>\n",
" <td>進行固形癌</td>\n",
" <td>Advanced solid tumor malignancies</td>\n",
" <td>第II/III相試験(NCT06225596)で使用予定のBT8009の用量について、単剤療...</td>\n",
" <td>1</td>\n",
" <td>NaN</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>1. Eastern Cooperative Oncology Group (ECOG) o...</td>\n",
" <td>1. Current treatment with strong inhibitors or...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>In Part A, (BT8009 monotherapy) participants w...</td>\n",
" <td>[Advanced solid tum, malignancies]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>157</th>\n",
" <td>jRCT2052240059</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>遺伝子HSD17B4高メチル化を有するHER2陽性ER陰性乳癌における非手術療法の有用性を評...</td>\n",
" <td>乳がん</td>\n",
" <td>乳がん</td>\n",
" <td>Breast cancer</td>\n",
" <td>HSD17B4高メチル化(HSD17B4 hypermethylation:HH)を有するH...</td>\n",
" <td>2</td>\n",
" <td>NaN</td>\n",
" <td>...</td>\n",
" <td>diagnostic purpose</td>\n",
" <td>1. Histologically confirmed invasive breast ca...</td>\n",
" <td>1. History of other malignancy within the last...</td>\n",
" <td>20age old over</td>\n",
" <td>No limit</td>\n",
" <td>Female</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Omitting breast surgery after preoperative che...</td>\n",
" <td>[Breast cancer]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>170</th>\n",
" <td>jRCT2031240096</td>\n",
" <td>NCT06380751</td>\n",
" <td>NaN</td>\n",
" <td>本治験の主要目的は、BRCA1、BRCA2 又は PALB2 変異を有し、HR 陽性、HER...</td>\n",
" <td>進行乳癌</td>\n",
" <td>進行乳癌</td>\n",
" <td>Advanced Breast Cancer</td>\n",
" <td>Treatment</td>\n",
" <td>3</td>\n",
" <td>NaN</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>- Adult females, pre/peri-menopausal and/or po...</td>\n",
" <td>- Participants with history of MDS/AML or with...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Experimental: Arm 1: saruparib (AZD5305) plus ...</td>\n",
" <td>[Advanced Breast Cancer]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>209</th>\n",
" <td>jRCT2031230750</td>\n",
" <td>NCT06188559</td>\n",
" <td>NaN</td>\n",
" <td>治療歴のある HER2 陽性又は HER2 低発現の切除不能又は転移性乳癌の被験者を対象に，...</td>\n",
" <td>HER2 陽性又は HER2 低発現の切除不能又は転移性乳癌</td>\n",
" <td>HER2 陽性又は HER2 低発現の切除不能又は転移性乳癌</td>\n",
" <td>HER2-positive or HER2-low unresectable or meta...</td>\n",
" <td>治療</td>\n",
" <td>2</td>\n",
" <td>NaN</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>(1) Male or female, aged >=18 years at the tim...</td>\n",
" <td>(1) Presence of brain or subdural metastases, ...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Generic Name:NA Study Treatment in dose optimi...</td>\n",
" <td>[HER2-positive, HER2-low unresectable, metasta...</td>\n",
" </tr>\n",
" <tr>\n",
" <th>215</th>\n",
" <td>jRCT2031230723</td>\n",
" <td>NCT06112379</td>\n",
" <td>NaN</td>\n",
" <td>未治療のトリプルネガティブ又はホルモン受容体低発現／HER2陰性乳癌の成人患者を対象として、...</td>\n",
" <td>乳癌</td>\n",
" <td>乳癌</td>\n",
" <td>Breast Cancer</td>\n",
" <td>未治療のトリプルネガティブ又はホルモン受容体低発現/HER2陰性乳癌の成人患者を対象として、...</td>\n",
" <td>3</td>\n",
" <td>NaN</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>1. Participant must be >= 18 years at the time...</td>\n",
" <td>1. As judged by the investigator, any evidence...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>- Experimental arm: Dato-DXd plus durvalumab n...</td>\n",
" <td>[Breast Cancer]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>224</th>\n",
" <td>jRCT2051230196</td>\n",
" <td>NCT06105632</td>\n",
" <td>NaN</td>\n",
" <td>CDK4/6 阻害薬による前治療で進行したホルモン受容体陽性HER2 陰性の進行または転移乳...</td>\n",
" <td>ホルモン受容体（HR）陽性ヒト上皮増殖因子受容体2（HER2）陰性の進行または転移乳癌</td>\n",
" <td>ホルモン受容体(HR)陽性ヒト上皮増殖因子受容体2(HER2)陰性の進行または転移乳癌</td>\n",
" <td>HR-positive, HER2-negative Advanced or Metasta...</td>\n",
" <td>CDK4/6阻害薬による前治療で進行したHR陽性HER2陰性の進行または転移乳癌患者を対象に...</td>\n",
" <td>3</td>\n",
" <td>NaN</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>* Histological confirmation of breast cancer w...</td>\n",
" <td>* Any medical or psychiatric condition that ma...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Arm A (Experimental Arm) PF-07220060 plus Fulv...</td>\n",
" <td>[HR-positive, HER2-negative Advanced, Metastat...</td>\n",
" </tr>\n",
" <tr>\n",
" <th>234</th>\n",
" <td>jRCT2031230677</td>\n",
" <td>NCT06206837</td>\n",
" <td>NaN</td>\n",
" <td>18歳以上のER陽性／HER2陰性の進行または転移乳癌患者を対象として，経口タンパク質分解誘...</td>\n",
" <td>エストロゲン受容体陽性／ヒト上皮増殖因子受容体 2 陰性の進行または転移乳癌</td>\n",
" <td>エストロゲン受容体陽性/ヒト上皮増殖因子受容体 2 陰性の進行または転移乳癌</td>\n",
" <td>ER+/HER2- advanced or metastatic breast cancer</td>\n",
" <td>進行乳癌患者を対象として,vepdegestrantとPF-07220060を併用投与したと...</td>\n",
" <td>1-2</td>\n",
" <td>NaN</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>Inclusion Criteria: * Histological or cytologi...</td>\n",
" <td>Exclusion Criteria: * visceral crisis at risk ...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Drug: vepdegestrant Daily oral dosages of vepd...</td>\n",
" <td>[ER+/HER2- advanced, metastatic breast cancer]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>240</th>\n",
" <td>jRCT2061230102</td>\n",
" <td>NCT06103864</td>\n",
" <td>NaN</td>\n",
" <td>Programmed death-ligand（PD-L1）陽性の局所再発手術不能又は転移性...</td>\n",
" <td>乳癌</td>\n",
" <td>乳癌</td>\n",
" <td>Breast Cancer</td>\n",
" <td>PD-L1陽性の局所再発手術不能または転移性TNBC患者を対象に、デュルバルマブ併用または非...</td>\n",
" <td>3</td>\n",
" <td>NaN</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>Histologically or cytologically documented loc...</td>\n",
" <td>As judged by investigator, severe or uncontrol...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Arm 1: Dato-DXd + durvalumab Arm 2: Investigat...</td>\n",
" <td>[Breast Cancer]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>307</th>\n",
" <td>jRCT2061230074</td>\n",
" <td>NCT05952557</td>\n",
" <td>NaN</td>\n",
" <td>根治的局所治療（化学療法の併用または非併用）を受けて疾患の兆候のない、再発リスクが中間～高リ...</td>\n",
" <td>乳がん、早期乳がん</td>\n",
" <td>乳がん、早期乳がん</td>\n",
" <td>Breast Cancer, Early Breast Cancer</td>\n",
" <td>Treatment</td>\n",
" <td>3</td>\n",
" <td>NaN</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>- Women and Men; 18 years or more at the time ...</td>\n",
" <td>- Inoperable locally advanced or metastatic br...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>arm A: continue with SoC ET as directed by inv...</td>\n",
" <td>[Breast Cancer, Early Breast Cancer]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>351</th>\n",
" <td>jRCT2031230279</td>\n",
" <td>NCT05862285</td>\n",
" <td>NaN</td>\n",
" <td>GENENTECH社及び／又はF.HOFFMANN-LA ROCHE LTDが依頼した試験に...</td>\n",
" <td>癌</td>\n",
" <td>癌</td>\n",
" <td>Cancer</td>\n",
" <td>本継続投与試験の目的は,親治験から移行する時点でまだ治験治療を受けており,その地域でその治療...</td>\n",
" <td>3</td>\n",
" <td>NaN</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>- Eligible for continuing Roche IMP-based ther...</td>\n",
" <td>- Meet any of the study treatment discontinuat...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Ipatasertib: Ipatasertib will be administered ...</td>\n",
" <td>[Cancer]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>392</th>\n",
" <td>jRCT2031230096</td>\n",
" <td>NCT05774951</td>\n",
" <td>NaN</td>\n",
" <td>根治的局所領域療法（化学療法の併用または非併用）および標準補助内分泌療法（ET）を少なくとも...</td>\n",
" <td>乳がん、早期乳がん</td>\n",
" <td>乳がん、早期乳がん</td>\n",
" <td>Breast Cancer, Early Breast Cancer</td>\n",
" <td>Treatment</td>\n",
" <td>3</td>\n",
" <td>NaN</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>- Women and Men, greater than or equal to 18 y...</td>\n",
" <td>- Inoperable locally advanced or metastatic br...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>arm A: continue with SoC ET as directed by inv...</td>\n",
" <td>[Breast Cancer, Early Breast Cancer]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>463</th>\n",
" <td>jRCT2061220087</td>\n",
" <td>NCT05629585</td>\n",
" <td>NaN</td>\n",
" <td>術前薬物療法後の外科的切除時に乳房及び／又は腋窩リンパ節に浸潤性残存病変を有するステージI～...</td>\n",
" <td>乳癌</td>\n",
" <td>乳癌</td>\n",
" <td>Breast Cancer</td>\n",
" <td>術前薬物療法後の外科的切除時に乳房および/または腋窩リンパ節に浸潤性残存病変を有するI~II...</td>\n",
" <td>3</td>\n",
" <td>NaN</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>Participant must be >= 18 years at the time of...</td>\n",
" <td>Stage IV (metastatic) TNBC. History of prior i...</td>\n",
" <td>18age old over</td>\n",
" <td>130age old under</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Arm 1: Dato-DXd 6 mg/kg IV Q3W x 8 cycles + Du...</td>\n",
" <td>[Breast Cancer]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>515</th>\n",
" <td>jRCT2031220276</td>\n",
" <td>NCT05307705</td>\n",
" <td>NaN</td>\n",
" <td>PIK3CA H1047R変異を有する進行乳がん患者及びその他の固形がん患者を対象としたLO...</td>\n",
" <td>乳がん</td>\n",
" <td>乳がん</td>\n",
" <td>Breast Cancer</td>\n",
" <td>LOXO-783 の単独投与及び他の抗がん剤との併用投与における 第 2 相試験の推奨用量、...</td>\n",
" <td>1</td>\n",
" <td>NaN</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>-Have advanced breast cancer or another solid ...</td>\n",
" <td>-Medical Conditions -Colorectal cancer -Endome...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>-Drug: LOXO-783 Oral Other Name: LY3849524 -Dr...</td>\n",
" <td>[Breast Cancer]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>555</th>\n",
" <td>jRCT2031220034</td>\n",
" <td>NCT04862663</td>\n",
" <td>NaN</td>\n",
" <td>局所進行（切除不能）又は転移性のホルモン受容体陽性／ヒト上皮細胞成長因子受容体2 陰性乳癌を...</td>\n",
" <td>局所進行（切除不能）又は転移性乳癌</td>\n",
" <td>局所進行(切除不能)又は転移性乳癌</td>\n",
" <td>Locally Advanced (Inoperable) or Metastatic Br...</td>\n",
" <td>Treatment</td>\n",
" <td>3</td>\n",
" <td>NaN</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>Key inclusion criteria for both phases: 1. Adu...</td>\n",
" <td>Key exclusion criteria for both phases: 1. His...</td>\n",
" <td>18age old over</td>\n",
" <td>99age old under</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Capivasertib: PO BD 4 days on /3 days off per ...</td>\n",
" <td>[Locally Advanced (Inoperable), Metastatic Bre...</td>\n",
" </tr>\n",
" <tr>\n",
" <th>590</th>\n",
" <td>jRCT2031210585</td>\n",
" <td>NCT05123482</td>\n",
" <td>NaN</td>\n",
" <td>進行又は転移性固形がん患者を対象としたAZD8205の単独療法及び他の抗がん剤との併用療法に...</td>\n",
" <td>乳癌、胆道癌、卵巣癌、子宮内膜癌</td>\n",
" <td>乳癌、胆道癌、卵巣癌、子宮内膜癌</td>\n",
" <td>Breast Cancer, Biliary Tract Carcinoma, Ovaria...</td>\n",
" <td>進行又は転移性固形がんに対する治療法候補としての新規化合物AZD8205の研究</td>\n",
" <td>1-2</td>\n",
" <td>NaN</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>- Age18 years or more - Relapsed/metastatic so...</td>\n",
" <td>- Treatment with any of the following: 1. Nitr...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Sub-study1 AZD8205 Monotherapy AZD8205 is an a...</td>\n",
" <td>[Breast Cancer, Biliary Tract Carcinoma, Ovari...</td>\n",
" </tr>\n",
" <tr>\n",
" <th>593</th>\n",
" <td>jRCT2031210560</td>\n",
" <td>NCT05061823</td>\n",
" <td>NaN</td>\n",
" <td>複数のBintrafusp alfa（M7824）臨床試験の被験者を対象に長期データを収集す...</td>\n",
" <td>固形癌</td>\n",
" <td>固形癌</td>\n",
" <td>Cancer</td>\n",
" <td>本治験は、実施中のbintrafusp alfaの親試験( (NCT02517398, NC...</td>\n",
" <td>3</td>\n",
" <td>NaN</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>- Participants who are currently enrolled in a...</td>\n",
" <td>- Participants who are pregnant or currently i...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Participants who are continuing treatment with...</td>\n",
" <td>[Cancer]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>629</th>\n",
" <td>jRCT2052210099</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>乳がんを有する成人女性及び健康成人女性を対象とした乳房用マイクロ波画像診断装置IGS-000...</td>\n",
" <td>乳がん</td>\n",
" <td>乳がん</td>\n",
" <td>Breast cancer</td>\n",
" <td>本治験の目的は,乳がん又はその疑いのある者,並びに乳がん又はその疑いがない者を対象に乳房画像...</td>\n",
" <td>2</td>\n",
" <td>NaN</td>\n",
" <td>...</td>\n",
" <td>screening</td>\n",
" <td>Breast cancer (including suspected) (1) One of...</td>\n",
" <td>(1) There is trauma with bleeding on the breas...</td>\n",
" <td>20age old over</td>\n",
" <td>No limit</td>\n",
" <td>Female</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>The test using IGS-0001 will be performed twic...</td>\n",
" <td>[Breast cancer]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>729</th>\n",
" <td>jRCT2031200057</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>治療抵抗性乳がんを対象としたTDM-812の腫瘍内投与法の安全性評価を目的とした第I相試験</td>\n",
" <td>乳がん</td>\n",
" <td>乳がん</td>\n",
" <td>Breast cancer</td>\n",
" <td>TDM-812の腫瘍内投与の安全性および忍容性を評価し、今後の臨床評価に用いる腫瘍内投与にお...</td>\n",
" <td>1</td>\n",
" <td>NaN</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td><Disease Characteristics> 1)Patients with inop...</td>\n",
" <td>1)Patients correspond to either of the followi...</td>\n",
" <td>20age old over</td>\n",
" <td>No limit</td>\n",
" <td>Female</td>\n",
" <td>NaN</td>\n",
" <td>Breast cancer</td>\n",
" <td>For the target tumor, the dose settled at each...</td>\n",
" <td>[Breast cancer]</td>\n",
" </tr>\n",
" </tbody>\n",
"</table>\n",
"<p>19 rows × 40 columns</p>\n",
"</div>"
],
"text/plain": [
" JRCT ID NCT No JapicCTI No \\\n",
"32 jRCT2031240476 NCT06312176 NaN \n",
"112 jRCT2031240238 NaN NaN \n",
"157 jRCT2052240059 NaN NaN \n",
"170 jRCT2031240096 NCT06380751 NaN \n",
"209 jRCT2031230750 NCT06188559 NaN \n",
"215 jRCT2031230723 NCT06112379 NaN \n",
"224 jRCT2051230196 NCT06105632 NaN \n",
"234 jRCT2031230677 NCT06206837 NaN \n",
"240 jRCT2061230102 NCT06103864 NaN \n",
"307 jRCT2061230074 NCT05952557 NaN \n",
"351 jRCT2031230279 NCT05862285 NaN \n",
"392 jRCT2031230096 NCT05774951 NaN \n",
"463 jRCT2061220087 NCT05629585 NaN \n",
"515 jRCT2031220276 NCT05307705 NaN \n",
"555 jRCT2031220034 NCT04862663 NaN \n",
"590 jRCT2031210585 NCT05123482 NaN \n",
"593 jRCT2031210560 NCT05061823 NaN \n",
"629 jRCT2052210099 NaN NaN \n",
"729 jRCT2031200057 NaN NaN \n",
"\n",
" Title \\\n",
"32 ホルモン受容体陽性・ヒト上皮成長因子受容体2陰性（HR+/HER2-）の切除不能な局所進行又... \n",
"112 ネクチン-4発現に関連する進行性悪性腫瘍を有する日本人患者を対象にBT8009の安全性、薬物... \n",
"157 遺伝子HSD17B4高メチル化を有するHER2陽性ER陰性乳癌における非手術療法の有用性を評... \n",
"170 本治験の主要目的は、BRCA1、BRCA2 又は PALB2 変異を有し、HR 陽性、HER... \n",
"209 治療歴のある HER2 陽性又は HER2 低発現の切除不能又は転移性乳癌の被験者を対象に，... \n",
"215 未治療のトリプルネガティブ又はホルモン受容体低発現／HER2陰性乳癌の成人患者を対象として、... \n",
"224 CDK4/6 阻害薬による前治療で進行したホルモン受容体陽性HER2 陰性の進行または転移乳... \n",
"234 18歳以上のER陽性／HER2陰性の進行または転移乳癌患者を対象として，経口タンパク質分解誘... \n",
"240 Programmed death-ligand（PD-L1）陽性の局所再発手術不能又は転移性... \n",
"307 根治的局所治療（化学療法の併用または非併用）を受けて疾患の兆候のない、再発リスクが中間～高リ... \n",
"351 GENENTECH社及び／又はF.HOFFMANN-LA ROCHE LTDが依頼した試験に... \n",
"392 根治的局所領域療法（化学療法の併用または非併用）および標準補助内分泌療法（ET）を少なくとも... \n",
"463 術前薬物療法後の外科的切除時に乳房及び／又は腋窩リンパ節に浸潤性残存病変を有するステージI～... \n",
"515 PIK3CA H1047R変異を有する進行乳がん患者及びその他の固形がん患者を対象としたLO... \n",
"555 局所進行（切除不能）又は転移性のホルモン受容体陽性／ヒト上皮細胞成長因子受容体2 陰性乳癌を... \n",
"590 進行又は転移性固形がん患者を対象としたAZD8205の単独療法及び他の抗がん剤との併用療法に... \n",
"593 複数のBintrafusp alfa（M7824）臨床試験の被験者を対象に長期データを収集す... \n",
"629 乳がんを有する成人女性及び健康成人女性を対象とした乳房用マイクロ波画像診断装置IGS-000... \n",
"729 治療抵抗性乳がんを対象としたTDM-812の腫瘍内投与法の安全性評価を目的とした第I相試験 \n",
"\n",
" TargetJ \\\n",
"32 HR+/HER2-の切除不能局所進行又は転移性乳癌の患者 \n",
"112 進行固形癌 \n",
"157 乳がん \n",
"170 進行乳癌 \n",
"209 HER2 陽性又は HER2 低発現の切除不能又は転移性乳癌 \n",
"215 乳癌 \n",
"224 ホルモン受容体（HR）陽性ヒト上皮増殖因子受容体2（HER2）陰性の進行または転移乳癌 \n",
"234 エストロゲン受容体陽性／ヒト上皮増殖因子受容体 2 陰性の進行または転移乳癌 \n",
"240 乳癌 \n",
"307 乳がん、早期乳がん \n",
"351 癌 \n",
"392 乳がん、早期乳がん \n",
"463 乳癌 \n",
"515 乳がん \n",
"555 局所進行（切除不能）又は転移性乳癌 \n",
"590 乳癌、胆道癌、卵巣癌、子宮内膜癌 \n",
"593 固形癌 \n",
"629 乳がん \n",
"729 乳がん \n",
"\n",
" Target \\\n",
"32 HR+/HER2-の切除不能局所進行又は転移性乳癌の患者 \n",
"112 進行固形癌 \n",
"157 乳がん \n",
"170 進行乳癌 \n",
"209 HER2 陽性又は HER2 低発現の切除不能又は転移性乳癌 \n",
"215 乳癌 \n",
"224 ホルモン受容体(HR)陽性ヒト上皮増殖因子受容体2(HER2)陰性の進行または転移乳癌 \n",
"234 エストロゲン受容体陽性/ヒト上皮増殖因子受容体 2 陰性の進行または転移乳癌 \n",
"240 乳癌 \n",
"307 乳がん、早期乳がん \n",
"351 癌 \n",
"392 乳がん、早期乳がん \n",
"463 乳癌 \n",
"515 乳がん \n",
"555 局所進行(切除不能)又は転移性乳癌 \n",
"590 乳癌、胆道癌、卵巣癌、子宮内膜癌 \n",
"593 固形癌 \n",
"629 乳がん \n",
"729 乳がん \n",
"\n",
" TargetEnglish \\\n",
"32 HR+/HER2 unresectable locally advanced or meta... \n",
"112 Advanced solid tumor malignancies \n",
"157 Breast cancer \n",
"170 Advanced Breast Cancer \n",
"209 HER2-positive or HER2-low unresectable or meta... \n",
"215 Breast Cancer \n",
"224 HR-positive, HER2-negative Advanced or Metasta... \n",
"234 ER+/HER2- advanced or metastatic breast cancer \n",
"240 Breast Cancer \n",
"307 Breast Cancer, Early Breast Cancer \n",
"351 Cancer \n",
"392 Breast Cancer, Early Breast Cancer \n",
"463 Breast Cancer \n",
"515 Breast Cancer \n",
"555 Locally Advanced (Inoperable) or Metastatic Br... \n",
"590 Breast Cancer, Biliary Tract Carcinoma, Ovaria... \n",
"593 Cancer \n",
"629 Breast cancer \n",
"729 Breast cancer \n",
"\n",
" 研究・治験の目的 試験等のフェーズ 試験の種類 ... \\\n",
"32 HR+/HER2-の切除不能な局所進行又は転移性乳癌患者を対象にMK-2870の単剤及びペム... 3 NaN ... \n",
"112 第II/III相試験(NCT06225596)で使用予定のBT8009の用量について、単剤療... 1 NaN ... \n",
"157 HSD17B4高メチル化(HSD17B4 hypermethylation:HH)を有するH... 2 NaN ... \n",
"170 Treatment 3 NaN ... \n",
"209 治療 2 NaN ... \n",
"215 未治療のトリプルネガティブ又はホルモン受容体低発現/HER2陰性乳癌の成人患者を対象として、... 3 NaN ... \n",
"224 CDK4/6阻害薬による前治療で進行したHR陽性HER2陰性の進行または転移乳癌患者を対象に... 3 NaN ... \n",
"234 進行乳癌患者を対象として,vepdegestrantとPF-07220060を併用投与したと... 1-2 NaN ... \n",
"240 PD-L1陽性の局所再発手術不能または転移性TNBC患者を対象に、デュルバルマブ併用または非... 3 NaN ... \n",
"307 Treatment 3 NaN ... \n",
"351 本継続投与試験の目的は,親治験から移行する時点でまだ治験治療を受けており,その地域でその治療... 3 NaN ... \n",
"392 Treatment 3 NaN ... \n",
"463 術前薬物療法後の外科的切除時に乳房および/または腋窩リンパ節に浸潤性残存病変を有するI~II... 3 NaN ... \n",
"515 LOXO-783 の単独投与及び他の抗がん剤との併用投与における 第 2 相試験の推奨用量、... 1 NaN ... \n",
"555 Treatment 3 NaN ... \n",
"590 進行又は転移性固形がんに対する治療法候補としての新規化合物AZD8205の研究 1-2 NaN ... \n",
"593 本治験は、実施中のbintrafusp alfaの親試験( (NCT02517398, NC... 3 NaN ... \n",
"629 本治験の目的は,乳がん又はその疑いのある者,並びに乳がん又はその疑いがない者を対象に乳房画像... 2 NaN ... \n",
"729 TDM-812の腫瘍内投与の安全性および忍容性を評価し、今後の臨床評価に用いる腫瘍内投与にお... 1 NaN ... \n",
"\n",
" purpose Inclusion Criteria \\\n",
"32 treatment purpose -Has unresectable locally advanced or metastat... \n",
"112 treatment purpose 1. Eastern Cooperative Oncology Group (ECOG) o... \n",
"157 diagnostic purpose 1. Histologically confirmed invasive breast ca... \n",
"170 treatment purpose - Adult females, pre/peri-menopausal and/or po... \n",
"209 treatment purpose (1) Male or female, aged >=18 years at the tim... \n",
"215 treatment purpose 1. Participant must be >= 18 years at the time... \n",
"224 treatment purpose * Histological confirmation of breast cancer w... \n",
"234 treatment purpose Inclusion Criteria: * Histological or cytologi... \n",
"240 treatment purpose Histologically or cytologically documented loc... \n",
"307 treatment purpose - Women and Men; 18 years or more at the time ... \n",
"351 treatment purpose - Eligible for continuing Roche IMP-based ther... \n",
"392 treatment purpose - Women and Men, greater than or equal to 18 y... \n",
"463 treatment purpose Participant must be >= 18 years at the time of... \n",
"515 treatment purpose -Have advanced breast cancer or another solid ... \n",
"555 treatment purpose Key inclusion criteria for both phases: 1. Adu... \n",
"590 treatment purpose - Age18 years or more - Relapsed/metastatic so... \n",
"593 treatment purpose - Participants who are currently enrolled in a... \n",
"629 screening Breast cancer (including suspected) (1) One of... \n",
"729 treatment purpose <Disease Characteristics> 1)Patients with inop... \n",
"\n",
" Exclusion Criteria Age Minimum \\\n",
"32 -Has breast cancer amenable to treatment with ... 18age old over \n",
"112 1. Current treatment with strong inhibitors or... 18age old over \n",
"157 1. History of other malignancy within the last... 20age old over \n",
"170 - Participants with history of MDS/AML or with... 18age old over \n",
"209 (1) Presence of brain or subdural metastases, ... 18age old over \n",
"215 1. As judged by the investigator, any evidence... 18age old over \n",
"224 * Any medical or psychiatric condition that ma... 18age old over \n",
"234 Exclusion Criteria: * visceral crisis at risk ... 18age old over \n",
"240 As judged by investigator, severe or uncontrol... 18age old over \n",
"307 - Inoperable locally advanced or metastatic br... 18age old over \n",
"351 - Meet any of the study treatment discontinuat... 18age old over \n",
"392 - Inoperable locally advanced or metastatic br... 18age old over \n",
"463 Stage IV (metastatic) TNBC. History of prior i... 18age old over \n",
"515 -Medical Conditions -Colorectal cancer -Endome... 18age old over \n",
"555 Key exclusion criteria for both phases: 1. His... 18age old over \n",
"590 - Treatment with any of the following: 1. Nitr... 18age old over \n",
"593 - Participants who are pregnant or currently i... 18age old over \n",
"629 (1) There is trauma with bleeding on the breas... 20age old over \n",
"729 1)Patients correspond to either of the followi... 20age old over \n",
"\n",
" Age Maximum Gender Discontinuation Criteria Keyword \\\n",
"32 No limit Both NaN NaN \n",
"112 No limit Both NaN NaN \n",
"157 No limit Female NaN NaN \n",
"170 No limit Both NaN NaN \n",
"209 No limit Both NaN NaN \n",
"215 No limit Both NaN NaN \n",
"224 No limit Both NaN NaN \n",
"234 No limit Both NaN NaN \n",
"240 No limit Both NaN NaN \n",
"307 No limit NaN NaN NaN \n",
"351 No limit Both NaN NaN \n",
"392 No limit Both NaN NaN \n",
"463 130age old under Both NaN NaN \n",
"515 No limit Both NaN NaN \n",
"555 99age old under Both NaN NaN \n",
"590 No limit Both NaN NaN \n",
"593 No limit Both NaN NaN \n",
"629 No limit Female NaN NaN \n",
"729 No limit Female NaN Breast cancer \n",
"\n",
" Intervention(s) \\\n",
"32 Arm A:MK-2870 Participants receive 4 mg/kg of ... \n",
"112 In Part A, (BT8009 monotherapy) participants w... \n",
"157 Omitting breast surgery after preoperative che... \n",
"170 Experimental: Arm 1: saruparib (AZD5305) plus ... \n",
"209 Generic Name:NA Study Treatment in dose optimi... \n",
"215 - Experimental arm: Dato-DXd plus durvalumab n... \n",
"224 Arm A (Experimental Arm) PF-07220060 plus Fulv... \n",
"234 Drug: vepdegestrant Daily oral dosages of vepd... \n",
"240 Arm 1: Dato-DXd + durvalumab Arm 2: Investigat... \n",
"307 arm A: continue with SoC ET as directed by inv... \n",
"351 Ipatasertib: Ipatasertib will be administered ... \n",
"392 arm A: continue with SoC ET as directed by inv... \n",
"463 Arm 1: Dato-DXd 6 mg/kg IV Q3W x 8 cycles + Du... \n",
"515 -Drug: LOXO-783 Oral Other Name: LY3849524 -Dr... \n",
"555 Capivasertib: PO BD 4 days on /3 days off per ... \n",
"590 Sub-study1 AZD8205 Monotherapy AZD8205 is an a... \n",
"593 Participants who are continuing treatment with... \n",
"629 The test using IGS-0001 will be performed twic... \n",
"729 For the target tumor, the dose settled at each... \n",
"\n",
" TargetWord \n",
"32 [HR+/HER2 unresectable locally advanced, metas... \n",
"112 [Advanced solid tum, malignancies] \n",
"157 [Breast cancer] \n",
"170 [Advanced Breast Cancer] \n",
"209 [HER2-positive, HER2-low unresectable, metasta... \n",
"215 [Breast Cancer] \n",
"224 [HR-positive, HER2-negative Advanced, Metastat... \n",
"234 [ER+/HER2- advanced, metastatic breast cancer] \n",
"240 [Breast Cancer] \n",
"307 [Breast Cancer, Early Breast Cancer] \n",
"351 [Cancer] \n",
"392 [Breast Cancer, Early Breast Cancer] \n",
"463 [Breast Cancer] \n",
"515 [Breast Cancer] \n",
"555 [Locally Advanced (Inoperable), Metastatic Bre... \n",
"590 [Breast Cancer, Biliary Tract Carcinoma, Ovari... \n",
"593 [Cancer] \n",
"629 [Breast cancer] \n",
"729 [Breast cancer] \n",
"\n",
"[19 rows x 40 columns]"
]
},
"execution_count": 53,
"metadata": {},
"output_type": "execute_result"
}
],
"source": [
"# ターゲットリスト全体を処理\n",
"matched_indices = []\n",
"target_vecs_list = []\n",
"cosine_scores_list = []\n",
"for idx, target_words in enumerate(basedf['TargetWord']):\n",
" # ターゲット内の各単語をベクトル化\n",
" target_vecs = model.encode(target_words, convert_to_tensor=True)\n",
" # コサイン類似度を計算\n",
" cosine_scores = util.cos_sim(query_vec, target_vecs).squeeze()\n",
" target_vecs_list.append(target_vecs)\n",
" cosine_scores_list.append(cosine_scores)\n",
" # 閾値を超えるか確認\n",
" if (cosine_scores >= threshold).any(): # いずれかが閾値を超えている場合\n",
" matched_indices.append(idx)\n",
"\n",
"# 抽出\n",
"matched_df = basedf.iloc[matched_indices]\n",
"matched_df"
]
},
{
"cell_type": "code",
"execution_count": 42,
"metadata": {},
"outputs": [],
"source": [
"# 全データのターゲット列をベクトル化\n",
"target_list = basedf['TargetEnglish'].tolist()\n",
"target_vecs = model.encode(target_list, convert_to_tensor=True)\n",
"# コサイン類似度を計算\n",
"cosine_scores = util.cos_sim(query_vec, target_vecs).squeeze()"
]
},
{
"cell_type": "code",
"execution_count": 43,
"metadata": {},
"outputs": [
{
"data": {
"text/html": [
"<div>\n",
"<style scoped>\n",
" .dataframe tbody tr th:only-of-type {\n",
" vertical-align: middle;\n",
" }\n",
"\n",
" .dataframe tbody tr th {\n",
" vertical-align: top;\n",
" }\n",
"\n",
" .dataframe thead th {\n",
" text-align: right;\n",
" }\n",
"</style>\n",
"<table border=\"1\" class=\"dataframe\">\n",
" <thead>\n",
" <tr style=\"text-align: right;\">\n",
" <th></th>\n",
" <th>JRCT ID</th>\n",
" <th>NCT No</th>\n",
" <th>JapicCTI No</th>\n",
" <th>Title</th>\n",
" <th>TargetJ</th>\n",
" <th>Target</th>\n",
" <th>TargetEnglish</th>\n",
" <th>研究・治験の目的</th>\n",
" <th>試験等のフェーズ</th>\n",
" <th>試験の種類</th>\n",
" <th>...</th>\n",
" <th>purpose</th>\n",
" <th>Inclusion Criteria</th>\n",
" <th>Exclusion Criteria</th>\n",
" <th>Age Minimum</th>\n",
" <th>Age Maximum</th>\n",
" <th>Gender</th>\n",
" <th>Discontinuation Criteria</th>\n",
" <th>Keyword</th>\n",
" <th>Intervention(s)</th>\n",
" <th>TargetWord</th>\n",
" </tr>\n",
" </thead>\n",
" <tbody>\n",
" <tr>\n",
" <th>157</th>\n",
" <td>jRCT2052240059</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>遺伝子HSD17B4高メチル化を有するHER2陽性ER陰性乳癌における非手術療法の有用性を評...</td>\n",
" <td>乳がん</td>\n",
" <td>乳がん</td>\n",
" <td>Breast cancer</td>\n",
" <td>HSD17B4高メチル化(HSD17B4 hypermethylation:HH)を有するH...</td>\n",
" <td>2</td>\n",
" <td>NaN</td>\n",
" <td>...</td>\n",
" <td>diagnostic purpose</td>\n",
" <td>1. Histologically confirmed invasive breast ca...</td>\n",
" <td>1. History of other malignancy within the last...</td>\n",
" <td>20age old over</td>\n",
" <td>No limit</td>\n",
" <td>Female</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Omitting breast surgery after preoperative che...</td>\n",
" <td>[Breast cancer]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>170</th>\n",
" <td>jRCT2031240096</td>\n",
" <td>NCT06380751</td>\n",
" <td>NaN</td>\n",
" <td>本治験の主要目的は、BRCA1、BRCA2 又は PALB2 変異を有し、HR 陽性、HER...</td>\n",
" <td>進行乳癌</td>\n",
" <td>進行乳癌</td>\n",
" <td>Advanced Breast Cancer</td>\n",
" <td>Treatment</td>\n",
" <td>3</td>\n",
" <td>NaN</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>- Adult females, pre/peri-menopausal and/or po...</td>\n",
" <td>- Participants with history of MDS/AML or with...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Experimental: Arm 1: saruparib (AZD5305) plus ...</td>\n",
" <td>[Advanced Breast Cancer]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>215</th>\n",
" <td>jRCT2031230723</td>\n",
" <td>NCT06112379</td>\n",
" <td>NaN</td>\n",
" <td>未治療のトリプルネガティブ又はホルモン受容体低発現／HER2陰性乳癌の成人患者を対象として、...</td>\n",
" <td>乳癌</td>\n",
" <td>乳癌</td>\n",
" <td>Breast Cancer</td>\n",
" <td>未治療のトリプルネガティブ又はホルモン受容体低発現/HER2陰性乳癌の成人患者を対象として、...</td>\n",
" <td>3</td>\n",
" <td>NaN</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>1. Participant must be >= 18 years at the time...</td>\n",
" <td>1. As judged by the investigator, any evidence...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>- Experimental arm: Dato-DXd plus durvalumab n...</td>\n",
" <td>[Breast Cancer]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>240</th>\n",
" <td>jRCT2061230102</td>\n",
" <td>NCT06103864</td>\n",
" <td>NaN</td>\n",
" <td>Programmed death-ligand（PD-L1）陽性の局所再発手術不能又は転移性...</td>\n",
" <td>乳癌</td>\n",
" <td>乳癌</td>\n",
" <td>Breast Cancer</td>\n",
" <td>PD-L1陽性の局所再発手術不能または転移性TNBC患者を対象に、デュルバルマブ併用または非...</td>\n",
" <td>3</td>\n",
" <td>NaN</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>Histologically or cytologically documented loc...</td>\n",
" <td>As judged by investigator, severe or uncontrol...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Arm 1: Dato-DXd + durvalumab Arm 2: Investigat...</td>\n",
" <td>[Breast Cancer]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>307</th>\n",
" <td>jRCT2061230074</td>\n",
" <td>NCT05952557</td>\n",
" <td>NaN</td>\n",
" <td>根治的局所治療（化学療法の併用または非併用）を受けて疾患の兆候のない、再発リスクが中間～高リ...</td>\n",
" <td>乳がん、早期乳がん</td>\n",
" <td>乳がん、早期乳がん</td>\n",
" <td>Breast Cancer, Early Breast Cancer</td>\n",
" <td>Treatment</td>\n",
" <td>3</td>\n",
" <td>NaN</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>- Women and Men; 18 years or more at the time ...</td>\n",
" <td>- Inoperable locally advanced or metastatic br...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>arm A: continue with SoC ET as directed by inv...</td>\n",
" <td>[Breast Cancer, Early Breast Cancer]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>351</th>\n",
" <td>jRCT2031230279</td>\n",
" <td>NCT05862285</td>\n",
" <td>NaN</td>\n",
" <td>GENENTECH社及び／又はF.HOFFMANN-LA ROCHE LTDが依頼した試験に...</td>\n",
" <td>癌</td>\n",
" <td>癌</td>\n",
" <td>Cancer</td>\n",
" <td>本継続投与試験の目的は,親治験から移行する時点でまだ治験治療を受けており,その地域でその治療...</td>\n",
" <td>3</td>\n",
" <td>NaN</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>- Eligible for continuing Roche IMP-based ther...</td>\n",
" <td>- Meet any of the study treatment discontinuat...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Ipatasertib: Ipatasertib will be administered ...</td>\n",
" <td>[Cancer]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>392</th>\n",
" <td>jRCT2031230096</td>\n",
" <td>NCT05774951</td>\n",
" <td>NaN</td>\n",
" <td>根治的局所領域療法（化学療法の併用または非併用）および標準補助内分泌療法（ET）を少なくとも...</td>\n",
" <td>乳がん、早期乳がん</td>\n",
" <td>乳がん、早期乳がん</td>\n",
" <td>Breast Cancer, Early Breast Cancer</td>\n",
" <td>Treatment</td>\n",
" <td>3</td>\n",
" <td>NaN</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>- Women and Men, greater than or equal to 18 y...</td>\n",
" <td>- Inoperable locally advanced or metastatic br...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>arm A: continue with SoC ET as directed by inv...</td>\n",
" <td>[Breast Cancer, Early Breast Cancer]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>463</th>\n",
" <td>jRCT2061220087</td>\n",
" <td>NCT05629585</td>\n",
" <td>NaN</td>\n",
" <td>術前薬物療法後の外科的切除時に乳房及び／又は腋窩リンパ節に浸潤性残存病変を有するステージI～...</td>\n",
" <td>乳癌</td>\n",
" <td>乳癌</td>\n",
" <td>Breast Cancer</td>\n",
" <td>術前薬物療法後の外科的切除時に乳房および/または腋窩リンパ節に浸潤性残存病変を有するI~II...</td>\n",
" <td>3</td>\n",
" <td>NaN</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>Participant must be >= 18 years at the time of...</td>\n",
" <td>Stage IV (metastatic) TNBC. History of prior i...</td>\n",
" <td>18age old over</td>\n",
" <td>130age old under</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Arm 1: Dato-DXd 6 mg/kg IV Q3W x 8 cycles + Du...</td>\n",
" <td>[Breast Cancer]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>515</th>\n",
" <td>jRCT2031220276</td>\n",
" <td>NCT05307705</td>\n",
" <td>NaN</td>\n",
" <td>PIK3CA H1047R変異を有する進行乳がん患者及びその他の固形がん患者を対象としたLO...</td>\n",
" <td>乳がん</td>\n",
" <td>乳がん</td>\n",
" <td>Breast Cancer</td>\n",
" <td>LOXO-783 の単独投与及び他の抗がん剤との併用投与における 第 2 相試験の推奨用量、...</td>\n",
" <td>1</td>\n",
" <td>NaN</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>-Have advanced breast cancer or another solid ...</td>\n",
" <td>-Medical Conditions -Colorectal cancer -Endome...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>-Drug: LOXO-783 Oral Other Name: LY3849524 -Dr...</td>\n",
" <td>[Breast Cancer]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>593</th>\n",
" <td>jRCT2031210560</td>\n",
" <td>NCT05061823</td>\n",
" <td>NaN</td>\n",
" <td>複数のBintrafusp alfa（M7824）臨床試験の被験者を対象に長期データを収集す...</td>\n",
" <td>固形癌</td>\n",
" <td>固形癌</td>\n",
" <td>Cancer</td>\n",
" <td>本治験は、実施中のbintrafusp alfaの親試験( (NCT02517398, NC...</td>\n",
" <td>3</td>\n",
" <td>NaN</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td>- Participants who are currently enrolled in a...</td>\n",
" <td>- Participants who are pregnant or currently i...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Participants who are continuing treatment with...</td>\n",
" <td>[Cancer]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>629</th>\n",
" <td>jRCT2052210099</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>乳がんを有する成人女性及び健康成人女性を対象とした乳房用マイクロ波画像診断装置IGS-000...</td>\n",
" <td>乳がん</td>\n",
" <td>乳がん</td>\n",
" <td>Breast cancer</td>\n",
" <td>本治験の目的は,乳がん又はその疑いのある者,並びに乳がん又はその疑いがない者を対象に乳房画像...</td>\n",
" <td>2</td>\n",
" <td>NaN</td>\n",
" <td>...</td>\n",
" <td>screening</td>\n",
" <td>Breast cancer (including suspected) (1) One of...</td>\n",
" <td>(1) There is trauma with bleeding on the breas...</td>\n",
" <td>20age old over</td>\n",
" <td>No limit</td>\n",
" <td>Female</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>The test using IGS-0001 will be performed twic...</td>\n",
" <td>[Breast cancer]</td>\n",
" </tr>\n",
" <tr>\n",
" <th>729</th>\n",
" <td>jRCT2031200057</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>治療抵抗性乳がんを対象としたTDM-812の腫瘍内投与法の安全性評価を目的とした第I相試験</td>\n",
" <td>乳がん</td>\n",
" <td>乳がん</td>\n",
" <td>Breast cancer</td>\n",
" <td>TDM-812の腫瘍内投与の安全性および忍容性を評価し、今後の臨床評価に用いる腫瘍内投与にお...</td>\n",
" <td>1</td>\n",
" <td>NaN</td>\n",
" <td>...</td>\n",
" <td>treatment purpose</td>\n",
" <td><Disease Characteristics> 1)Patients with inop...</td>\n",
" <td>1)Patients correspond to either of the followi...</td>\n",
" <td>20age old over</td>\n",
" <td>No limit</td>\n",
" <td>Female</td>\n",
" <td>NaN</td>\n",
" <td>Breast cancer</td>\n",
" <td>For the target tumor, the dose settled at each...</td>\n",
" <td>[Breast cancer]</td>\n",
" </tr>\n",
" </tbody>\n",
"</table>\n",
"<p>12 rows × 40 columns</p>\n",
"</div>"
],
"text/plain": [
" JRCT ID NCT No JapicCTI No \\\n",
"157 jRCT2052240059 NaN NaN \n",
"170 jRCT2031240096 NCT06380751 NaN \n",
"215 jRCT2031230723 NCT06112379 NaN \n",
"240 jRCT2061230102 NCT06103864 NaN \n",
"307 jRCT2061230074 NCT05952557 NaN \n",
"351 jRCT2031230279 NCT05862285 NaN \n",
"392 jRCT2031230096 NCT05774951 NaN \n",
"463 jRCT2061220087 NCT05629585 NaN \n",
"515 jRCT2031220276 NCT05307705 NaN \n",
"593 jRCT2031210560 NCT05061823 NaN \n",
"629 jRCT2052210099 NaN NaN \n",
"729 jRCT2031200057 NaN NaN \n",
"\n",
" Title TargetJ Target \\\n",
"157 遺伝子HSD17B4高メチル化を有するHER2陽性ER陰性乳癌における非手術療法の有用性を評... 乳がん 乳がん \n",
"170 本治験の主要目的は、BRCA1、BRCA2 又は PALB2 変異を有し、HR 陽性、HER... 進行乳癌 進行乳癌 \n",
"215 未治療のトリプルネガティブ又はホルモン受容体低発現／HER2陰性乳癌の成人患者を対象として、... 乳癌 乳癌 \n",
"240 Programmed death-ligand（PD-L1）陽性の局所再発手術不能又は転移性... 乳癌 乳癌 \n",
"307 根治的局所治療（化学療法の併用または非併用）を受けて疾患の兆候のない、再発リスクが中間～高リ... 乳がん、早期乳がん 乳がん、早期乳がん \n",
"351 GENENTECH社及び／又はF.HOFFMANN-LA ROCHE LTDが依頼した試験に... 癌 癌 \n",
"392 根治的局所領域療法（化学療法の併用または非併用）および標準補助内分泌療法（ET）を少なくとも... 乳がん、早期乳がん 乳がん、早期乳がん \n",
"463 術前薬物療法後の外科的切除時に乳房及び／又は腋窩リンパ節に浸潤性残存病変を有するステージI～... 乳癌 乳癌 \n",
"515 PIK3CA H1047R変異を有する進行乳がん患者及びその他の固形がん患者を対象としたLO... 乳がん 乳がん \n",
"593 複数のBintrafusp alfa（M7824）臨床試験の被験者を対象に長期データを収集す... 固形癌 固形癌 \n",
"629 乳がんを有する成人女性及び健康成人女性を対象とした乳房用マイクロ波画像診断装置IGS-000... 乳がん 乳がん \n",
"729 治療抵抗性乳がんを対象としたTDM-812の腫瘍内投与法の安全性評価を目的とした第I相試験 乳がん 乳がん \n",
"\n",
" TargetEnglish \\\n",
"157 Breast cancer \n",
"170 Advanced Breast Cancer \n",
"215 Breast Cancer \n",
"240 Breast Cancer \n",
"307 Breast Cancer, Early Breast Cancer \n",
"351 Cancer \n",
"392 Breast Cancer, Early Breast Cancer \n",
"463 Breast Cancer \n",
"515 Breast Cancer \n",
"593 Cancer \n",
"629 Breast cancer \n",
"729 Breast cancer \n",
"\n",
" 研究・治験の目的 試験等のフェーズ 試験の種類 ... \\\n",
"157 HSD17B4高メチル化(HSD17B4 hypermethylation:HH)を有するH... 2 NaN ... \n",
"170 Treatment 3 NaN ... \n",
"215 未治療のトリプルネガティブ又はホルモン受容体低発現/HER2陰性乳癌の成人患者を対象として、... 3 NaN ... \n",
"240 PD-L1陽性の局所再発手術不能または転移性TNBC患者を対象に、デュルバルマブ併用または非... 3 NaN ... \n",
"307 Treatment 3 NaN ... \n",
"351 本継続投与試験の目的は,親治験から移行する時点でまだ治験治療を受けており,その地域でその治療... 3 NaN ... \n",
"392 Treatment 3 NaN ... \n",
"463 術前薬物療法後の外科的切除時に乳房および/または腋窩リンパ節に浸潤性残存病変を有するI~II... 3 NaN ... \n",
"515 LOXO-783 の単独投与及び他の抗がん剤との併用投与における 第 2 相試験の推奨用量、... 1 NaN ... \n",
"593 本治験は、実施中のbintrafusp alfaの親試験( (NCT02517398, NC... 3 NaN ... \n",
"629 本治験の目的は,乳がん又はその疑いのある者,並びに乳がん又はその疑いがない者を対象に乳房画像... 2 NaN ... \n",
"729 TDM-812の腫瘍内投与の安全性および忍容性を評価し、今後の臨床評価に用いる腫瘍内投与にお... 1 NaN ... \n",
"\n",
" purpose Inclusion Criteria \\\n",
"157 diagnostic purpose 1. Histologically confirmed invasive breast ca... \n",
"170 treatment purpose - Adult females, pre/peri-menopausal and/or po... \n",
"215 treatment purpose 1. Participant must be >= 18 years at the time... \n",
"240 treatment purpose Histologically or cytologically documented loc... \n",
"307 treatment purpose - Women and Men; 18 years or more at the time ... \n",
"351 treatment purpose - Eligible for continuing Roche IMP-based ther... \n",
"392 treatment purpose - Women and Men, greater than or equal to 18 y... \n",
"463 treatment purpose Participant must be >= 18 years at the time of... \n",
"515 treatment purpose -Have advanced breast cancer or another solid ... \n",
"593 treatment purpose - Participants who are currently enrolled in a... \n",
"629 screening Breast cancer (including suspected) (1) One of... \n",
"729 treatment purpose <Disease Characteristics> 1)Patients with inop... \n",
"\n",
" Exclusion Criteria Age Minimum \\\n",
"157 1. History of other malignancy within the last... 20age old over \n",
"170 - Participants with history of MDS/AML or with... 18age old over \n",
"215 1. As judged by the investigator, any evidence... 18age old over \n",
"240 As judged by investigator, severe or uncontrol... 18age old over \n",
"307 - Inoperable locally advanced or metastatic br... 18age old over \n",
"351 - Meet any of the study treatment discontinuat... 18age old over \n",
"392 - Inoperable locally advanced or metastatic br... 18age old over \n",
"463 Stage IV (metastatic) TNBC. History of prior i... 18age old over \n",
"515 -Medical Conditions -Colorectal cancer -Endome... 18age old over \n",
"593 - Participants who are pregnant or currently i... 18age old over \n",
"629 (1) There is trauma with bleeding on the breas... 20age old over \n",
"729 1)Patients correspond to either of the followi... 20age old over \n",
"\n",
" Age Maximum Gender Discontinuation Criteria Keyword \\\n",
"157 No limit Female NaN NaN \n",
"170 No limit Both NaN NaN \n",
"215 No limit Both NaN NaN \n",
"240 No limit Both NaN NaN \n",
"307 No limit NaN NaN NaN \n",
"351 No limit Both NaN NaN \n",
"392 No limit Both NaN NaN \n",
"463 130age old under Both NaN NaN \n",
"515 No limit Both NaN NaN \n",
"593 No limit Both NaN NaN \n",
"629 No limit Female NaN NaN \n",
"729 No limit Female NaN Breast cancer \n",
"\n",
" Intervention(s) \\\n",
"157 Omitting breast surgery after preoperative che... \n",
"170 Experimental: Arm 1: saruparib (AZD5305) plus ... \n",
"215 - Experimental arm: Dato-DXd plus durvalumab n... \n",
"240 Arm 1: Dato-DXd + durvalumab Arm 2: Investigat... \n",
"307 arm A: continue with SoC ET as directed by inv... \n",
"351 Ipatasertib: Ipatasertib will be administered ... \n",
"392 arm A: continue with SoC ET as directed by inv... \n",
"463 Arm 1: Dato-DXd 6 mg/kg IV Q3W x 8 cycles + Du... \n",
"515 -Drug: LOXO-783 Oral Other Name: LY3849524 -Dr... \n",
"593 Participants who are continuing treatment with... \n",
"629 The test using IGS-0001 will be performed twic... \n",
"729 For the target tumor, the dose settled at each... \n",
"\n",
" TargetWord \n",
"157 [Breast cancer] \n",
"170 [Advanced Breast Cancer] \n",
"215 [Breast Cancer] \n",
"240 [Breast Cancer] \n",
"307 [Breast Cancer, Early Breast Cancer] \n",
"351 [Cancer] \n",
"392 [Breast Cancer, Early Breast Cancer] \n",
"463 [Breast Cancer] \n",
"515 [Breast Cancer] \n",
"593 [Cancer] \n",
"629 [Breast cancer] \n",
"729 [Breast cancer] \n",
"\n",
"[12 rows x 40 columns]"
]
},
"execution_count": 43,
"metadata": {},
"output_type": "execute_result"
}
],
"source": [
"matched_indices_d = (cosine_scores >= threshold).nonzero().tolist()\n",
"# 入れ子リストをフラットなリストに変換\n",
"flat_indices_d = [idx[0] for idx in matched_indices_d]\n",
"\n",
"# 抽出\n",
"matched_df_d = basedf.iloc[flat_indices_d]\n",
"matched_df_d\n"
]
},
{
"cell_type": "markdown",
"metadata": {},
"source": []
},
{
"cell_type": "markdown",
"metadata": {},
"source": [
"\n"
]
},
{
"cell_type": "markdown",
"metadata": {},
"source": []
}
],
"metadata": {
"kernelspec": {
"display_name": "gradio",
"language": "python",
"name": "python3"
},
"language_info": {
"codemirror_mode": {
"name": "ipython",
"version": 3
},
"file_extension": ".py",
"mimetype": "text/x-python",
"name": "python",
"nbconvert_exporter": "python",
"pygments_lexer": "ipython3",
"version": "3.12.3"
}
},
"nbformat": 4,
"nbformat_minor": 2
}
|